Trial reportCancer cell2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
Registry-linked trialAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03618641 (Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.Annals of oncology : official journal of the European Society for Medical Oncology · 2026Guideline
- Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).Frontiers in immunology · 2026Pooled it
- Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.Journal for immunotherapy of cancer · 2025Trial
- Mitochondrial Imaging Detects Early Cardiac Changes Following Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- An MRI-visible nanotheranostic establishes a self-amplifying pyroptosis-STING-IFN-β circuit for CD8Materials today. Bio · 2026Article
- Toward a Dual-Axis Model of Microbiome Modulation in Cancer Immunotherapy: Pathobiont Elimination and Functional Ecosystem Restoration.Cellular and molecular bioengineering · 2026Article
- Updates on intratumoral therapies in melanoma.Cancer · 2026Review
- Spatial Immunology in Translation: Linking Immune Organisation to Therapeutic Outcome.Medical sciences (Basel, Switzerland) · 2026Review
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Review
- Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?Journal for immunotherapy of cancer · 2026Review
- Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization.Nature reviews. Clinical oncology · 2026Review
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
- Microbiome modulation in cancer immunotherapy.Nature medicine · 2026Article
- A photothermal immune hydrogel dressing for enhanced post-melanoma resection treatment.Journal of nanobiotechnology · 2026Article
- Macrophages: Targets for next-generation cancer immunotherapy.Cancer cell · 2026Review
- Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy-Treated Melanoma.Cancer immunology research · 2026Article
- Priorities for local immunotherapy research and drug development.Journal for immunotherapy of cancer · 2026Review
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors.
Diwakar DavarDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: davard@upmc.edu.
Robert M MorrisonDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA.
Amiran K DzutsevLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Arivarasan KarunamurthyUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
Joe-Marc ChauvinDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Florent AmatoreDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
Julie S DeutschDivision of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA.
Rodrigo X Das NevesDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
Richard R RodriguesBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
John A McCullochGenetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Hong WangDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
Douglas J HartmanUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Jonathan H BadgerGenetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Miriam R FernandesLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Yulong BaiDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
Jie SunDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
Alicia M ColeLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Poonam AggarwalLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Jennifer R FangLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Christopher DeitrickDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Riyue BaoDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
Umamaheswar DuvvuriUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
Shaum S SridharanUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
Seungwon W KimUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
Haroon A ChoudryUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Matthew P HoltzmanUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
James F PingpankUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
James Patrick O'TooleUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Plastic Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
Richelle DeBlasioDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Yang JinDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Quanquan DingDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Wentao GaoDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Christopher GroetschDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Ornella PaglianoDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Amy RoseDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Corey UrbanDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Jagjit SinghUniversity of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
Prajan DivarkarNanostring Technologies, Seattle, WA, USA.
David MauroCheckmate Pharmaceuticals, Cambridge, MA, USA.
Dmitri BobilevCheckmate Pharmaceuticals, Cambridge, MA, USA.
James WooldridgeCheckmate Pharmaceuticals, Cambridge, MA, USA.
Arthur M KriegCheckmate Pharmaceuticals, Cambridge, MA, USA.
Matthew G FuryRegeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Jeffrey R WhiteakerTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Lei ZhaoTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Amanda G PaulovichTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Yana G NajjarDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
Jason J LukeDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
John M KirkwoodDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
Janis M TaubeDivision of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA; Tumor Microenvironment Core, Bloomberg-Kimmel Institute of Immunotherapy, Mark Foundation Center for Advanced Imaging and Genomics, Johns Hopkins University, Baltimore, MD, USA.
Hyun Jung ParkDepartment of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA.
Giorgio TrinchieriLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: trinchig@mail.nih.gov.
Hassane M ZarourDivision of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: zarourhm@upmc.edu.
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dan Paul Zandberg · 1988 to 2026
$158.0MProject 5: Microenvironment manipulation using anti-angiogenics to improve immunotherapy in melanomaP50CA254865 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZAROUR, HASSANE M · 2021 to 2025
$10.4MProteogenomic studies to understand mechanisms and drivers of resistance to immunotherapiesU01CA271407 · NCI · FRED HUTCHINSON CANCER CENTER · PI Diwakar Davar, AMANDA G PAULOVICH · 2022 to 2026
$5.6MNeoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in MelanomaR01CA257265 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVAR, DIWAKAR, ZAROUR, HASSANE M · 2021 to 2025
$2.6MFecal Microbiota Transplant and PD-1 blockade in MelanomaR01CA222203 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZAROUR, HASSANE M · 2018 to 2022
$2.5MTherapy with fecal microbiota transplantation and immune checkpoint blockade for solid tumorsU01CA268806 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HASSANE M ZAROUR · 2022 to 2026
$2.4MHigh-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574kNCI NIH HHS P30 CA047904NCI NIH HHS P50 CA254865NCI NIH HHS R01 CA222203NCI NIH HHS R01 CA257265NCI NIH HHS U01 CA268806NCI NIH HHS U01 CA271407NIH HHS S10 OD028483
Abstract
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR was associated with necrosis, and melanophagocytosis with increased CD8
Indexed as
MelanomaNeoadjuvant TherapyNivolumabAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleGastrointestinal MicrobiomeHumansImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMaleMiddle AgedProspective StudiesTumor MicroenvironmentImmune Checkpoint InhibitorsNivolumabICIimmunotherapyinnate agonistmacrophagemelanomaneoadjuvantPD-1pDCTLR9vidutolimod
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03618641ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.